Literature DB >> 17393066

Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis.

K Rejdak1, A Petzold, T Kocki, J Kurzepa, P Grieb, W A Turski, Z Stelmasiak.   

Abstract

The study aimed to assay the cerebrospinal fluid (CSF) levels of protein S100B, a biomarker of astrocyte activation in relation to kynurenic acid (KYNA) and nitric oxide (NO) metabolites, nitrate/nitrite (NOx) concentrations in acute relapse multiple sclerosis (MS) patients. Twenty relapsing-remitting MS (RR-MS) patients and 10 controls were enrolled. RR-MS patients were assessed on the expanded disability status scale (EDSS) and underwent lumbar puncture. The CSF KYNA, NOx and S100B levels were significantly higher in RR-MS group compared to controls (p = 0.01, 0.001, 0.04, respectively). There was a significant correlation between CSF S100B and KYNA (p = 0.01) but not NOx (p > 0.05) in RR-MS. CSF KYNA, NOx or S100B concentrations did not correlate with disease characteristics of MS patients. Our study suggests the activation of the kynurenine pathway leading to the increase of neuroprotective KYNA in the CSF of MS patients during acute relapse what contrasts with chronic phases of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393066     DOI: 10.1007/s00702-007-0667-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  34 in total

1.  Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation with disease activity.

Authors:  J Drulović; I Dujmović; S Mesaros; T Samardzić; D Maksimović; N Stojsavljević; Z Lević; M Mostarica Stojokvić
Journal:  Mult Scler       Date:  2001-02       Impact factor: 6.312

Review 2.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

Review 3.  Secondary progressive multiple sclerosis: current knowledge and future challenges.

Authors:  Marco Rovaris; Christian Confavreux; Roberto Furlan; Ludwig Kappos; Giancarlo Comi; Massimo Filippi
Journal:  Lancet Neurol       Date:  2006-04       Impact factor: 44.182

4.  Kynurenine metabolism in multiple sclerosis.

Authors:  Z Hartai; P Klivenyi; T Janaky; B Penke; L Dux; L Vecsei
Journal:  Acta Neurol Scand       Date:  2005-08       Impact factor: 3.209

5.  S100 beta stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes.

Authors:  J Hu; F Castets; J L Guevara; L J Van Eldik
Journal:  J Biol Chem       Date:  1996-02-02       Impact factor: 5.157

6.  Evidence for increased nitric oxide production in multiple sclerosis.

Authors:  A W Johnson; J M Land; E J Thompson; J P Bolaños; J B Clark; S J Heales
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

7.  Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis.

Authors:  A Chiarugi; A Cozzi; C Ballerini; L Massacesi; F Moroni
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

8.  Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course.

Authors:  A Svenningsson; A S Petersson; O Andersen; G K Hansson
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

9.  Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage.

Authors:  Kenneth E Hill; Lauren V Zollinger; Hilary E Watt; Noel G Carlson; John W Rose
Journal:  J Neuroimmunol       Date:  2004-06       Impact factor: 3.478

Review 10.  The role of nitric oxide in multiple sclerosis.

Authors:  Kenneth J Smith; Hans Lassmann
Journal:  Lancet Neurol       Date:  2002-08       Impact factor: 44.182

View more
  23 in total

1.  Urinary kynurenine as a biomarker for Parkinson's disease.

Authors:  Jia-He Bai; Ya-Li Zheng; Yong-Peng Yu
Journal:  Neurol Sci       Date:  2020-07-13       Impact factor: 3.307

2.  Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.

Authors:  Giacomo Lazzarino; Angela M Amorini; Axel Petzold; Claudio Gasperini; Serena Ruggieri; Maria Esmeralda Quartuccio; Giuseppe Lazzarino; Enrico Di Stasio; Barbara Tavazzi
Journal:  Mol Neurobiol       Date:  2016-11-08       Impact factor: 5.590

Review 3.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

4.  S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis.

Authors:  Andreia Barateiro; Vera Afonso; Gisela Santos; João José Cerqueira; Dora Brites; Jack van Horssen; Adelaide Fernandes
Journal:  Mol Neurobiol       Date:  2015-07-17       Impact factor: 5.590

Review 5.  The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications.

Authors:  Judit Füvesi; Cecilia Rajda; Krisztina Bencsik; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-01-19       Impact factor: 3.575

Review 6.  The potential roles of amino acids and their major derivatives in the management of multiple sclerosis.

Authors:  Somayeh Pashaei; Reza Yarani; Pantea Mohammadi; Mohammad Sajad Emami Aleagha
Journal:  Amino Acids       Date:  2022-04-26       Impact factor: 3.520

7.  Effects of S100B on Serotonergic Plasticity and Neuroinflammation in the Hippocampus in Down Syndrome and Alzheimer's Disease: Studies in an S100B Overexpressing Mouse Model.

Authors:  Lee A Shapiro; Lynn A Bialowas-McGoey; Patricia M Whitaker-Azmitia
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-22

Review 8.  Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.

Authors:  Dániel Sandi; Zsanett Fricska-Nagy; Krisztina Bencsik; László Vécsei
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

9.  Serum metabolic profile in multiple sclerosis patients.

Authors:  Barbara Tavazzi; Anna Paola Batocchi; Angela Maria Amorini; Viviana Nociti; Serafina D'Urso; Salvatore Longo; Stefano Gullotta; Marika Picardi; Giuseppe Lazzarino
Journal:  Mult Scler Int       Date:  2011-06-28

10.  Understanding the roles of the kynurenine pathway in multiple sclerosis progression.

Authors:  Chai K Lim; Bruce J Brew; Gayathri Sundaram; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2010-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.